drugset / Trial / NCT05990465
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I, interventional, single arm, open label, treatment study designed to evaluate the safety and efficacy of LV20.19 CAR -T cells with pirtobrutinib bridging and maintenance in adult patients with B cell malignancies that have failed prior therapies.
Timeline
- Start
- 2025-02-06
- Primary completion
- 2026-07
- Completion
- 2027-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LV20.19 CAR T cells | Cell therapy | 2.5e+06 cells/kg | Intravenous |
| Subject | Pirtobrutinib | Other / unclassified | 200 mg | Oral |